Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
RA McCutcheon, RSE Keefe, PK McGuire - Molecular psychiatry, 2023 - nature.com
Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …
functioning associated with the disorder and are not responsive to existing treatments. In this …
Reinforcement learning in healthcare: A survey
As a subfield of machine learning, reinforcement learning (RL) aims at optimizing decision
making by using interaction samples of an agent with its environment and the potentially …
making by using interaction samples of an agent with its environment and the potentially …
[HTML][HTML] Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
Abstract Changes over 50 years of research on antipsychotics in schizophrenia have
occurred. A scientometric synthesis of such changes over time and a measure of …
occurred. A scientometric synthesis of such changes over time and a measure of …
Cognitive deficits in psychotic disorders: a lifespan perspective
Individuals with disorders that include psychotic symptoms (ie psychotic disorders)
experience broad cognitive impairments in the chronic state, indicating a dimension of …
experience broad cognitive impairments in the chronic state, indicating a dimension of …
Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
SJ Kaar, S Natesan, R Mccutcheon, OD Howes - Neuropharmacology, 2020 - Elsevier
Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …
disorders but are ineffective for some patients and associated with side-effects and …
[HTML][HTML] A non–D2-receptor-binding drug for the treatment of schizophrenia
KS Koblan, J Kent, SC Hopkins… - … England Journal of …, 2020 - Mass Medical Soc
Background An oral compound, SEP-363856, that does not act on dopamine D2 receptors
but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5 …
but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5 …
[HTML][HTML] Schizophrenia: overview and treatment options
KR Patel, J Cherian, K Gohil… - Pharmacy and …, 2014 - ncbi.nlm.nih.gov
Schizophrenia: Overview and Treatment Options - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
Schizophrenia is a cognitive illness: time for a change in focus
Schizophrenia is currently classified as a psychotic disorder. This article posits that this
emphasis on psychosis is a conceptual fallacy that has greatly contributed to the lack of …
emphasis on psychosis is a conceptual fallacy that has greatly contributed to the lack of …
Animal models of neuropsychiatric disorders
EJ Nestler, SE Hyman - Nature neuroscience, 2010 - nature.com
Modeling of human neuropsychiatric disorders in animals is extremely challenging given the
subjective nature of many symptoms, the lack of biomarkers and objective diagnostic tests …
subjective nature of many symptoms, the lack of biomarkers and objective diagnostic tests …
Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations
A McCleery, KH Nuechterlein - Dialogues in clinical neuroscience, 2019 - Taylor & Francis
Despite effective pharmacological treatments for psychotic symptoms (eg, hallucinations,
delusions), functional outcomes for people with psychotic disorders are often disappointing …
delusions), functional outcomes for people with psychotic disorders are often disappointing …